What else do you expect, they need the approval first to do the clinical trials....keep in mind that their medical report was peer reviewed 'independently' and deem to be pausible by experience/highly credential ppls (which the FDA will take into account)....I see a similar run as AMBS (when their FDA was approved) but even higher given they are in the stem-cell/cancer medical field.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.